News Image

Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX.

By Mill Chart

Last update: Dec 1, 2023

Our stock screener has singled out NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as an attractive growth opportunity. NASDAQ:NBIX is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.

Exploring NASDAQ:NBIX's Growth

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:NBIX has earned a 9 for growth:

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 226.32%, which is quite impressive.
  • The Earnings Per Share has been growing by 66.75% on average over the past years. This is a very strong growth
  • NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.46%.
  • Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 55.91% on average per year.
  • Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 50.12% on average per year.
  • NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.42% yearly.

Deciphering NASDAQ:NBIX's Valuation Rating

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:NBIX has achieved a 6 out of 10:

  • Based on the Price/Earnings ratio, NBIX is valued cheaply inside the industry as 94.15% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 95.82% of the companies listed in the same industry.
  • 94.48% of the companies in the same industry are more expensive than NBIX, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 95.65% of the companies listed in the same industry.
  • The excellent profitability rating of NBIX may justify a higher PE ratio.
  • A more expensive valuation may be justified as NBIX's earnings are expected to grow with 65.62% in the coming years.

ChartMill's Evaluation of Health

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 7 out of 10:

  • NBIX has an Altman-Z score of 9.41. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • NBIX has a better Altman-Z score (9.41) than 88.80% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 2.39 indicates that NBIX has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.34 indicates that NBIX has no problem at all paying its short term obligations.

Profitability Analysis for NASDAQ:NBIX

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 8 out of 10:

  • NBIX has a better Return On Assets (6.71%) than 96.49% of its industry peers.
  • NBIX has a Return On Equity of 9.54%. This is amongst the best in the industry. NBIX outperforms 95.65% of its industry peers.
  • NBIX's Return On Invested Capital of 12.95% is amongst the best of the industry. NBIX outperforms 96.99% of its industry peers.
  • The last Return On Invested Capital (12.95%) for NBIX is above the 3 year average (12.37%), which is a sign of increasing profitability.
  • Looking at the Profit Margin, with a value of 10.71%, NBIX belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • NBIX has a Operating Margin of 19.50%. This is amongst the best in the industry. NBIX outperforms 96.66% of its industry peers.
  • NBIX has a better Gross Margin (97.82%) than 97.32% of its industry peers.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Our latest full fundamental report of NBIX contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (4/26/2024, 7:05:57 PM)

After market: 135.99 0 (0%)

135.99

-1.77 (-1.28%)

NBIX News

News Image3 days ago - Investor's Business DailyStock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

News Image5 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...

News Image5 days ago - InvestorPlace3 Red-Hot Biotech Rockets Blasting Off in 2024

The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.

News Image6 days ago - Investor's Business DailyNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win

The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.

News Image13 days ago - Sentia Medical Sciences, Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
News Image18 days ago - ChartmillWhy NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

News Image19 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...

News Image19 days ago - ChartmillFor those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

News Image26 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...

News Imagea month ago - Investor's Business DailyS&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

NBIX Links
Follow us for more